John Trizzino - 14 Dec 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, CCO and CBO
Signature
/s/ Mark Casey, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
14 Dec 2023
Net transactions value
-$4,398
Form type
4
Filing time
18 Dec 2023, 17:12:26 UTC
Previous filing
22 Aug 2023
Next filing
26 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +1,600 +16% 11,428 14 Dec 2023 Direct F1
transaction NVAX Common Stock Tax liability $4,398 -773 -6.8% $5.69 10,655 14 Dec 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -1,600 -100% $0.000000* 0 14 Dec 2023 Common Stock 1,600 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units ("RSU"s) subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.
F2 The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
F3 Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.